Aligos Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Aligos Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $18.30 million for the year ending 2025.

  • Aligos Therapeutics, Inc. showed a decrease of -50.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Aligos Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 73.7%.
  • Historical annual values: Fiscal year 2025: $18.30 million | Fiscal year 2024: $37.00 million | Fiscal year 2023: $135.70 million | Fiscal year 2022: $81.35 million | Fiscal year 2021: $186.82 million | Fiscal year 2020: $220.38 million | Fiscal year 2019: $69.57 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: